- 期刊
2021年COVID-19疫苗檢驗封緘放行分析
Annual Report on Batch Release of COVID-19 Vaccine in Taiwan, 2021
摘要
食品藥物管理署執行2021年度COVID-19疫苗檢驗封緘，為瞭解COVID-19疫苗檢驗封緘數量及國產COVID-19疫苗自製率，特整理分析相關數據以供未來接種疫苗策略之參考。2021年度完成檢驗封緘之COVID-19疫苗共119批，總計43,355,908劑，經逐批審查與檢驗合格後，核發封緘證明書並放行，提供國人進行疫苗接種，強化民眾保護力並降低疫情傳播，維護國家防疫安全。至2021年止國內計有3款疫苗通過專案輸入許可包含：AstraZeneca COVID-19 Vaccine（Vaxzevria）、Moderna COVID-19 Vaccine（Spikevax）與BioNTech COVID-19 Vaccine（Comirnaty），以及1款專案製造許可：高端新冠肺炎疫苗（MVC COVID-19 Vaccine），其中放行最大劑量數為AstraZeneca COVID-19 Vaccine（Vaxzevria） 14,562,450劑，其次為BioNTech COVID-19Vaccine（Comirnaty） 13,285,884劑，而國產高端新冠肺炎疫苗計5,396,274劑僅占比約12.45％，可見國產疫苗自製率尚有進步空間，未來期望能提升國內疫苗產能，確保國人疫苗使用量能。
並列摘要
This report analyzed the data of COVID-19 vaccine batch released by the Taiwan Food and Drug Administration in 2021. It reveals the cases of COVID-19 vaccine lot released and rate of domestic manufactured, and could be used as a reference for the vaccination strategies in the future. In 2021, 119 batches of COVID-19 vaccine with a total of 43,355,908 doses have been released in batch. After all test results of these products have been complied to the respective company's specifications, the Certificate of Lot Release of Biologics is issued. The qualified products could be vaccinated for domestic people to improve the protection and block the spread of the epidemic. By 2021, three national company of COVID-19 vaccines (AstraZeneca COVID-19 Vaccine (Vaxzevria), Moderna COVID-19 Vaccine (Spikevax) and BioNTech COVID-19 Vaccine (Comirnaty) and one domestic manufactured product (MVC COVID-19 Vaccine) were announced the issuance of Emergency Use Authorization (EUA). The report showed that the highest doses released company of COVID-19 vaccine was the AstraZeneca (14,562,450 doses), followed by BioNTech (13,285,884 doses). The proportion for MVC COVID-19 Vaccine was only 12.45% (5,396,274 doses), suggested that the rate of domestic manufactured still has a long way to go. In the future, to ensure the availability of vaccines for domestic people, it is important to improve the domestic manufactured capacity.
延伸閱讀
- 葉明叡、歐晁瑋（2022）。COVID-19疫苗強制接種政策之跨國比較。疫情報導，38(12)，132-147。https://doi.org/10.6524/EB.202206_38(12).0001
- 許瑜真、吳慧娟、徐悅芳、陳蓓諭、江正榮（2020）。COVID-19：全球疫苗研發進程與公平分配機制初探。疫情報導，36(16)，259-267。https://doi.org/10.6524/EB.202008_36(16).0002
- 陳易徵、蘇士閔、許鐈云、曾泓儒、沈翰祖、廖宜倫（2023）。我國種子檢查室2021年檢測服務回顧。種苗科技專訊，(121)，5-8。https://www.airitilibrary.com/Article/Detail?DocID=10219455-N202305200005-00003
- 陳怡頻、杜慧珍、李書芬、林孟潔、許家銓、王博譽、曾素香、王德原（2020）。Annual Report on Batch Release of Blood Products in Taiwan, 2019。食品藥物研究年報，(11)，432-436。https://www.airitilibrary.com/Article/Detail?DocID=22195718-202012-202101210008-202101210008-432-436
- 李禹辰、羅郁茹、曾德瑜、楊博文、黃琴喨、吳明美、祁若鳳、林建良（2022）。The Impact of COVID-19 Pandemic on Drug Supply Chain of Taiwan。食品藥物研究年報，(13)，327-333。https://www.airitilibrary.com/Article/Detail?DocID=22195718-N202301090006-00037